NCT00186017View on ClinicalTrials.gov

Short Term Rescue Study of Olanzapine

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Bipolar Disorder
Interventions
DRUG

Olanzapine/Zyprexa

Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Stanford University

OTHER

NCT00186017 - Short Term Rescue Study of Olanzapine | Biotech Hunter | Biotech Hunter